Connor, Clark & Lunn Investment Management Ltd. Sarepta Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 2,053 shares of SRPT stock, worth $316,572. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,053Holding current value
$316,572% of portfolio
0.0%Shares
13 transactions
Others Institutions Holding SRPT
# of Institutions
470Shares Held
79.3MCall Options Held
4.23MPut Options Held
1.21M-
Vanguard Group Inc Valley Forge, PA8.8MShares$1.36 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY5.96MShares$919 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X04.89MShares$754 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA4.82MShares$743 Million0.13% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.34MShares$670 Million6.78% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $13.5B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...